Healthcare Industry News: computer-aided detection
News Release - March 12, 2008
iCAD Appoints John DeLucia as Vice President of Quality Assurance and Regulatory AffairsNASHUA, N.H., March 12 (HSMN NewsFeed) -- iCAD, Inc. (Nasdaq: ICAD ), an industry-leading provider of computer-aided detection (CAD) solutions for the early detection of cancer, today announced that John DeLucia has joined iCAD as the Vice President of Quality Assurance and Regulatory Affairs, reporting to iCAD President and CEO Ken Ferry. Mr. DeLucia brings more than 25 years of medical device, in-vitro diagnostics and biomedical research experience to this key management position. Mr. DeLucia has significant experience working with the FDA and other global regulatory authorities, and will be responsible for navigating iCAD through several anticipated FDA milestones. His expertise includes managing and directing regulatory submissions, compliance, clinical studies, quality assurance and laboratory services for medical device and clinical diagnostic products.
"I am especially pleased to be joining iCAD at this exciting time, as we have an opportunity to bring several compelling cancer screening technologies through the regulatory process and on to commercialization," said Mr. DeLucia. "I look forward to being an integral part of iCAD's success."
Prior to joining iCAD, Mr. DeLucia served as Vice President of Regulatory Affairs, Clinical Affairs and Quality Assurance at Z-Tech Medical Inc., a medical device company that developed a novel bioimpedance breast scanning detection system. Mr. DeLucia was responsible for directing and managing clinical trials, global regulatory submissions, facility quality operations and reporting, and regulatory compliance activities.
Before joining Z-Tech Medical Inc., Mr. DeLucia was Vice President of Regulatory Affairs, Clinical Affairs and Quality Assurance at Microsulis Americas, Inc., a medical device company that manufactures endometrial ablation systems for gynecological markets worldwide. Prior to that, he served as the Division Vice President of Quality Assurance for the Critical Care Division at Smiths Medical Critical Care, which develops and manufactures Class I and II anesthesia, respiratory, needle safety devices, and a wide variety of critical care devices. During his career he has also worked at companies such as ACMI Corporation, Genzyme, C.R. Bard and Pfizer.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of computer-aided detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by more than 1800 women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.
For iCAD, contact Darlene Deptula-Hicks, EVP and CFO at 603-882-5200 x7944 or via email at email@example.com
For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at firstname.lastname@example.org
For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via email at email@example.com
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release, including but not limited to, statements about the Company's confidence or strategies or expectations about revenues, results of operations, timing of regulatory approval of products or market opportunities, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.